Phase-I Study of the new B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 as Monotherapy or in Combination with Zanubrutinib (zanu) in Patients (pat) with B-Cell Malignancies: preliminary Data

被引：0
|
作者：
Stilgenbauer, S. [1 ]
Opat, S. [2 ,3 ]
Cheah, C. Y. [4 ,5 ,6 ,7 ]
Lasica, M. [8 ]
Verner, E. [9 ,10 ]
Browett, P. J. [11 ]
Chan, H. [12 ]
Soumerai, J. D. [13 ]
Gonzalez, Barca E. [14 ]
Hilger, J. [15 ]
Fang, Y. [16 ]
Simpson, D. [15 ]
Tam, C. S. [17 ,18 ,19 ]
机构：
[1] Univ Ulm, Ulm, Germany
[2] Monash Hlth, Clayton, Australia
[3] Monash Univ, Clayton, Australia
[4] Sir Charles Gairdner Hosp, Nedlands, Australia
[5] Pathwest Lab Med, Nedlands, Australia
[6] Univ Western Australia, Sch Med, Crawley, Australia
[7] Linear Clin Res, Nedlands, Australia
[8] St Vincents Hosp Melbourne, Fitzroy, Australia
[9] Concord Repatriat Gen Hosp, Concord, Australia
[10] Univ Sydney, Sydney, Australia
[11] Auckland City Hosp, Auckland, New Zealand
[12] North Shore Hosp, Auckland, New Zealand
[13] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[14] Univ Barcelona, Inst Catala Oncol Hosp, Barcelona, Spain
[15] BeiGene USA Inc, San Mateo, CA USA
[16] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[17] Peter MacCallum Canc Ctr, Melbourne, Australia
[18] Univ Melbourne, Parkville, Australia
[19] Royal Melbourne Hosp, Parkville, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V91
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [21] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
    Shadman, Mazyar
    Sharman, Jeff P.
    Levy, Moshe Y.
    Misleh, Jamal
    Zafar, Syed F.
    Freeman, Benjamin B.
    Burke, John M.
    Cultrera, Jennifer L.
    Yimer, Habte A.
    Chen, Dih-Yih
    Zhang, Xiaoping
    Cohen, Aileen
    Ro, Sunhee
    Huang, Jane
    Flinn, Ian W.
    BLOOD, 2020, 136
  • [22] BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma
    Schuetz, Johanna M.
    Johnson, Nathalie A.
    Morin, Ryan D.
    Hirst, Martin
    Zhao, Yongjun
    Tam, Angela
    Moore, Richard
    Zeng, Thomas
    Marra, Marco A.
    Connors, Joseph M.
    Brooks-Wilson, Angela R.
    Gascoyne, Randy D.
    BLOOD, 2010, 116 (21) : 1702 - 1703
  • [23] Interpreting MYC and BCL2 in diffuse large B-cell lymphoma
    Lai, Catherine
    Grant, Cliona
    Dunleavy, Kieron
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2091 - 2092
  • [24] Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.
    Shadman, Mazyar
    Sharman, Jeff Porter
    Levy, Moshe Y.
    Porter, Ryan
    Zafar, Syed Farhan
    Burke, John M.
    Chaudhry, Arvind
    Freeman, Benjamin Bruce
    Misleh, Jamal Ghazi
    Yimer, Habte Aragaw
    Cultrera, Jennifer L.
    Guthrie, Troy H.
    Kingsley, Ed
    Rao, Subramanya S.
    Chen, Dih-Yih
    Cohen, Aileen
    Feng, Shibao
    Huang, Jane
    Flinn, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Prognostic outcomes of diffuse large B-cell lymphoma patients with myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) co-expression
    Supanut Kumjan
    Kantang Satayasoontorn
    Kasidid Lawongsa
    Chonlada Laoruangroj
    Journal of Hematopathology, 2025, 18 (1)
  • [26] Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies
    Xu, Linlin
    Shadman, Mazyar
    Ponakala, Anusha
    Flinn, Ian W.
    Levy, Moshe Yair
    Porter, Ryan
    Burke, John M.
    Zafar, Syed F.
    Cultrera, Jennifer L.
    Misleh, Jamal
    Kingsley, Edwin C.
    Yimer, Habte
    Freeman, Benjamin
    Chaudhry, Arvind
    Tumula, Praveen K.
    Gandhi, Mitul
    Cohen, Aileen
    Chen, Dih-Yih
    Manda, Sudhir
    Sharman, Jeff P.
    Ramakrishnan, Vanitha
    BLOOD, 2022, 140 : 9269 - 9271
  • [27] Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
    Wawire, Jonathan
    Sayed, Shahin
    Moloo, Zahir
    Sohani, Aliyah R.
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 8
  • [28] High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
    Scott, David W.
    King, Rebecca L.
    Staiger, Annette M.
    Ben-Neriah, Susana
    Jiang, Aixiang
    Horn, Heike
    Mottok, Anja
    Farinha, Pedro
    Slack, Graham W.
    Ennishi, Daisuke
    Schmitz, Norbert
    Pfreundschuh, Michael
    Nowakowski, Grzegorz S.
    Kahl, Brad S.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Ott, German
    Macon, William R.
    Rosenwald, Andreas
    BLOOD, 2018, 131 (18) : 2060 - 2064
  • [29] Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements
    Ocal, Jon L.
    Feldman, Andrew L.
    Greipp, Patricia T.
    Rimsza, Lisa M.
    JOURNAL OF HEMATOPATHOLOGY, 2022, 15 (03) : 151 - 155
  • [30] Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements
    Jon L. Ocal
    Andrew L. Feldman
    Patricia T. Greipp
    Lisa M. Rimsza
    Journal of Hematopathology, 2022, 15 : 151 - 155
12345